Nancy J Devlin

List of Publications by Year
in descending order

114 papers	**8,429** citations	101543 **36** h-index	49909 **87** g-index
119 all docs	**119** docs citations	**119** times ranked	**10841** citing authors

#	Article	IF	Citations
1	Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review. Quality of Life Research, 2022, 31, 79-89.	3.1	9
2	How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents. Pharmacoeconomics, 2022, 40, 157-182.	3.3	8
3	A Comparison of PROPr and EQ-5D-5L Value Sets. Pharmacoeconomics, 2022, 40, 297-307.	3.3	14
4	The relationship between physical and mental health multimorbidity and children's health-related quality of life. Quality of Life Research, 2022, 31, 2119-2131.	3.1	11
5	Longitudinal study of patients' health-related quality of life using EQ-5D-3L in 11 Swedish National Quality Registers. BMJ Open, 2022, 12, e048176.	1.9	8
6	Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures. Pharmacoeconomics, 2022, 40, 379-431.	3.3	28
7	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. Value in Health, 2022, , .	0.3	2
8	The Development of the EQ-5D-5L and its Value Sets. , 2022, , 1-12.		8
9	Guidance to Users of EQ-5D-5L Value Sets. , 2022, , 213-233.		3
10	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine, 2022, 40, 4008-4016.	3.8	12
11	Preference Elicitation Techniques Used in Valuing Children's Health-Related Quality-of-Life: A Systematic Review. Pharmacoeconomics, 2022, 40, 663-698.	3.3	5
12	Valuing Child Health Isn't Child's Play. Value in Health, 2022, 25, 1087-1089.	0.3	8
13	Giving a Voice to Marginalised Groups for Health Care Decision Making. Patient, 2021, 14, 5-10.	2.7	6
14	Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?. Medical Decision Making, 2021, 41, 584-596.	2.4	30
15	Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. Health Economics (United Kingdom), 2021, 30, 1950-1977.	1.7	8
16	EQ-5D-5L Health-State Values for the Mexican Population. Applied Health Economics and Health Policy, 2021, 19, 905-914.	2.1	11
17	Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?. Applied Health Economics and Health Policy, 2021, 19, 635-644.	2.1	8
18	Psychometric Performance of HRQoL Measures: An Australian Paediatric Multi-Instrument Comparison Study Protocol (P-MIC). Children, 2021, 8, 714.	1.5	9

#	Article	IF	Citations
19	Variations in Patients' Overall Assessment of Their Health Across and Within Disease Groups Using the EQ-5D Questionnaire: Protocol for a Longitudinal Study in the Swedish National Quality Registers. JMIR Research Protocols, 2021, 10, e27669.	1.0	4
20	Sugammadex, neostigmine and postoperative pulmonary complications: an international randomised feasibility and pilot trial. Pilot and Feasibility Studies, 2021, 7, 200.	1.2	8
21	International guidelines for self-report and proxy completion of paediatric health-related quality of life measures: a protocol for a systematic review. BMJ Open, 2021, 11, e052049.	1.9	2
22	Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?. Pharmacoeconomics, 2020, 38, 325-340.	3.3	86
23	A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead'. Social Science and Medicine, 2020, 246, 112707.	3.8	31
24	Methods for Analysing and Reporting EQ-5D Data. , 2020, , .		125
25	The EQ-5D-5L Value Set for England: Response to the "Quality Assurance". Value in Health, 2020, 23, 649-655.	0.3	16
26	An exploration of methods for obtaining 0‰=‰dead anchors for latent scale EQ-5D-Y values. European Journal of Health Economics, 2020, 21, 1091-1103.	2.8	36
27	Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5‰L valuation study in Ireland. Health Policy, 2020, 124, 639-646.	3.0	4
28	International Valuation Protocol for the EQ-5D-Y-3L. Pharmacoeconomics, 2020, 38, 653-663.	3.3	84
29	An Introduction to EQ-5D Instruments and Their Applications. , 2020, , 1-22.		16
30	Analysis of EQ-5D Profiles. , 2020, , 23-49.		13
31	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. Journal of Patient-Reported Outcomes, 2020, 4, 22.	1.9	6
32	Analysis of EQ VAS Data. , 2020, , 51-59.		1
33	Analysis of EQ-5D Values. , 2020, , 61-86.		9
34	Health today versus health tomorrow: does Australia really care less about its future health than other countries do?. Australian Health Review, 2020, 44, 337.	1.1	5
35	A new method for valuing health: directly eliciting personal utility functions. European Journal of Health Economics, 2019, 20, 257-270.	2.8	26
36	Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. European Journal of Health Economics, 2019, 20, 99-105.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?. Value in Health, 2019, 22, 45-49.	0.3	31
38	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. Medical Decision Making, 2019, 39, 605-616.	2.4	42
39	All Male Panels and Other Diversity Considerations for ISPOR. PharmacoEconomics - Open, 2019, 3, 423-426.	1.8	0
40	A note on the relationship between age and health-related quality of life assessment. Quality of Life Research, 2019, 28, 1201-1205.	3.1	6
41	Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups. Value in Health, 2019, 22, 355-361.	0.3	10
42	Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management. Journal of Wound Care, 2018, 27, 156-165.	1.2	8
43	3L, 5L, What the L? A NICE Conundrum. Pharmacoeconomics, 2018, 36, 637-640.	3.3	28
44	Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. Pharmacoeconomics, 2018, 36, 699-713.	3.3	74
45	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). PharmacoEconomics - Open, 2018, 2, 153-163.	1.8	22
46	New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics (United Kingdom), 2018, 27, 23-38.	1.7	61
47	Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment. European Journal of Health Economics, 2018, 19, 595-605.	2.8	8
48	Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.7	863
49	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.3	70
50	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	10.7	66
51	Euthanasia, religiosity and the valuation of health states: results from an Irish EQ5D5L valuation study and their implications for anchor values. Health and Quality of Life Outcomes, 2018, 16, 152.	2.4	8
52	Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. Pharmacoeconomics, 2018, 36, 1345-1353.	3.3	67
53	A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?. Applied Health Economics and Health Policy, 2017, 15, 469-477.	2.1	16
54	EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 2017, 15, 127-137.	2.1	684

#	ARTICLE	IF	CITATIONS
55	Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Quality of Life Research, 2017, 26, 1187-1195.	3.1	5
56	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Quality of Life Research, 2017, 26, 2067-2078.	3.1	27
57	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. European Journal of Health Economics, 2017, 18, 967-977.	2.8	8
58	Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. Patient, 2017, 10, 677-686.	2.7	8
59	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health and Quality of Life Outcomes, 2017, 15, 130.	2.4	27
60	QALYs as a measure of value in cancer. Journal of Cancer Policy, 2017, 11, 19-25.	1.4	38
61	The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. BMJ Open, 2017, 7, e016969.	1.9	19
62	What Determines the Shape of an EQ-5D Index Distribution?. Medical Decision Making, 2016, 36, 941-951.	2.4	33
63	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
64	Opportunity costs and local health service spending decisions: a qualitative study from Wales. BMC Health Services Research, 2016, 16, 103.	2.2	19
65	Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 1-13.	0.3	437
66	Assessing Patient-Reported Outcomes in Pediatric Populations With Vaccine-Preventable Infectious Diseases: A Systematic Review of the Literature (the PROCHID Study). Value in Health, 2016, 19, 109-119.	0.3	3
67	Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, 2016, 19, 255-266.	0.3	19
68	Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 125-137.	0.3	320
69	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. International Journal of Technology Assessment in Health Care, 2015, 31, 363-370.	0.5	6
70	INTER-PROVIDER COMPARISON OF PATIENT-REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX. Health Economics (United Kingdom), 2015, 24, 41-54.	1.7	22
71	The Influence of Cost-Effectiveness and Other Factors on Nice Decisions. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Ov	1.7	166
72	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates. Value in Health Regional Issues, 2015, 7, 34-41.	1.2	20

#	ARTICLE	IF	CITATIONS
73	Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?. Health and Quality of Life Outcomes, 2015, 13, 171.	2.4	124
74	Association between market concentration of hospitals and patient health gain following hip replacement surgery. Journal of Health Services Research and Policy, 2015, 20, 11-17.	1.7	19
75	Putting patient-reported outcomes on the 'Big Data Road Map'. Journal of the Royal Society of Medicine, 2015, 108, 299-303.	2.0	34
76	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics, 2015, 33, 867-877.	3.3	45
77	Local health care expenditure plans and their opportunity costs. Health Policy, 2015, 119, 1237-1244.	3.0	16
78	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
79	What Determines the Shape of an EQ-5D Index Distribution?. SSRN Electronic Journal, 2014, , .	0.4	2
80	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 2014, 52, 935-943.	2.4	38
81	A Study of the Relationship between Health and Subjective Well-Being in Parkinson's Disease Patients. Value in Health, 2014, 17, 372-379.	0.3	27
82	A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol. Value in Health, 2014, 17, 445-453.	0.3	341
83	Assessing the performance of the EQ-VAS in the NHS PROMs programme. Quality of Life Research, 2014, 23, 977-989.	3.1	192
84	Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data. Health Services and Delivery Research, 2014, 2, 1-90.	1.4	20
85	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Health Technology Assessment, 2014, 18, vii-xxvi, 1-191.	2.8	47
86	A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock	1.7	51
87	The development of new research methods for the valuation of EQ-5D-5L. European Journal of Health Economics, 2013, 14, 1-3.	2.8	205
88	The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. European Journal of Health Economics, 2013, 14, 15-24.	2.8	24
89	Lead versus lag-time trade-off variants: does it make any difference?. European Journal of Health Economics, 2013, 14, 25-31.	2.8	33
90	Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. European Journal of Health Economics, 2013, 14, 43-51.	2.8	25

#	ARTICLE	IF	CITATIONS
91	One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. European Journal of Health Economics, 2013, 14, 65-73.	2.8	23
92	Operationalizing Value-Based Pricing of Medicines. Pharmacoeconomics, 2013, 31, 1-10.	3.3	84
93	Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions. Medical Decision Making, 2013, 33, 804-818.	2.4	39
94	The Influence of Cost-Effectiveness and Other Factors on NICE Decisions. SSRN Electronic Journal, 2013, , .	0.4	9
95	Comparison of the Underlying Constructs of the EQ-5D and Oxford Hip Score: Implications for Mapping. Value in Health, 2011, 14, 884-891.	0.3	26
96	A uniform time trade off method for states better and worse than dead: feasibility study of the â€˜lead timeâ€™ approach. Health Economics (United Kingdom), 2011, 20, 348-361.	1.7	111
97	Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Quality of Life Research, 2010, 19, 875-886.	3.1	574
98	Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life Research, 2010, 19, 887-897.	3.1	325
99	Patientâ€reported outcome measures in the NHS: new methods for analysing and reporting EQâ€5D data. Health Economics (United Kingdom), 2010, 19, 886-905.	1.7	206
100	Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review. Medical Decision Making, 2010, 30, 610-619.	2.4	56
101	Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?. Medical Decision Making, 2010, 30, 556-565.	2.4	76
102	The Economics of a â€˜Liberatedâ€™ NHS. Pharmacoeconomics, 2010, 28, 1075-1078.	3.3	3
103	An Analysis of NICEÊ¼s â€˜Restrictedâ€™ (or â€˜Optimizedâ€™) Decisions. Pharmacoeconomics, 2010, 28, 987-993.	3.3	21
104	â€œYesâ€, â€œNoâ€or â€œYes, butâ€? Multinomial modelling of NICE decision-making. Health Policy, 2006, 77, 352-367.	3.0	112
105	Is there a case for using visual analogue scale valuations in cost-utility analysis?. Health Economics (United Kingdom), 2006, 15, 653-664.	1.7	155
106	Does NICE have a costâ€effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics (United Kingdom), 2004, 13, 437-452.	1.7	609
107	Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Economics (United Kingdom), 2003, 12, 529-544.	1.7	81
108	PRIORITIZING PATIENTS FOR ELECTIVE SURGERY. International Journal of Technology Assessment in Health Care, 2003, 19, 91-105.	0.5	47

#	Article	IF	Citations
109	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates. SSRN Electronic Journal, 0, , .	0.4	1
110	Assessing the Performance of the EQ-VAS in the NHS PROMs Programme. SSRN Electronic Journal, 0, , .	0.4	3
111	Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches. SSRN Electronic Journal, 0, , .	0.4	2
112	A Comparison of Alternative Variants of the Lead and Lag Time TTO. SSRN Electronic Journal, 0, , .	0.4	2
113	Time to Tweak the TTO: But How?. SSRN Electronic Journal, 0, , .	0.4	0
114	The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states. Wellcome Open Research, 0, 7, 14.	1.8	7